Clinical Value of Combined Detection of Serum sTim-3 and CEA or CA19-9 for Postoperative Recurrence of Colorectal Cancer Diagnosis

Figures & data

Table 1 Serum Indices of Control, Benign Colorectal Tumors, After Surgery for CRC (Including Recurrence and No Recurrence)

Index		Control (n = 67)	Benign Colorectal Tumors (n = 21)	After Surgery for CRC (n = 90)	After Surgery for CRC (n = 90)
					Recurrence After Surgery (n = 52)	Recurrence-free After Surgery (n = 38)
Sex	Male	33 (49.3%)	11 (52.4%)	50 (55.6%)	28 (53.8%)	22 (57.9%)
	Female	34 (50.7%)	10 (47.6%)	40 (44.4%)	24 (46.2%)	16 (42.1%)
Age (years)		52.47±15.61	61.14±12.03	62.09±11.12	61.56±11.13	62.28±12.22
sTim-3 (ng/mL)		8.95±3.34	8.39±2.28	15.94±11.24	20.33±13.04	9.94±2.36
CEA (ng/mL)		1.79±1.04	3.35±4.02	92.42±334.26	124.33±414.86	48.75±167.72
CA19-9 (ng/mL)		9.51±9.481	1.51±6.22	279.34±767.37	455.62±964.44	31.59±117.37

Figure 1 Serum sTim-3 levels in each group.

Figure 2 The ROC curve of a single test of serum sTim-3 in each group.

Figure 3 The ROC curve of a single test of serum CEA in detecting postoperative recurrence of CRC (Postoperative recurrence vs Postoperative recurrence-free).

Figure 4 The ROC curve of a single test of serum CA19-9 in detecting postoperative recurrence of CRC (Postoperative recurrence vs Postoperative recurrence-free).

Figure 5 Comparison of the combination of serum sTim-3 with CEA and a single CEA test in diagnosing recurrence after CRC surgery.

Figure 6 Comparison of the combination of serum sTim-3 with CA19-9 and a single CA19-9 test in diagnosing recurrence after CRC surgery.